Figure 1. Event free survival (EFS) and overall survival (OS) of pediatric AML patients with and without EMI at initial diagnosis (A, B); Regarding pediatric AML patients with EMI at initial diagnosis, EFS and OS of patients with MS and CNS only (C, D). OS of relapse patients with and without EMI (E); OS of relapse patients with MS and CNS only (F).
The implication of SCT and GO treatment on the prognosis of patients with EMI at initial diagnosis.
Additionally, we evaluated the prognostic significance of SCT in first CR and GO treatment for patients with EMI at initial diagnosis. The data revealed that SCT in the first CR did not significantly affect either EFS or OS in patients with EMI at initial diagnosis (p >0.05) (Figs. 2A and 2B), whereas patients received GO treatment displayed potentially prolonger OS (p=0.0811 by log-rank test, and p=0.0399 by Wilcoxon test) while maintaining similar EFS (p=0.1610) compared to those who did not receive GO treatment (Figs. 2C and 2D).